The effects of obesity and obesity-related conditions on colorectal cancer prognosis

Cancer Control

Volumn 17, Issue 1, 2010, Pages 52-57

  Siegel, Erin M ^a   Ulrich, Cornelia M ^b,c   Poole, Elizabeth M ^b   Holmes, Rebecca S ^b   Jacobsen, Paul B ^a   Shibata, David ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; SOMATOMEDIN;

ARTICLE; BODY SIZE; BODY WEIGHT; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL RESEARCH; COLORECTAL CANCER; DIABETES MELLITUS; DIETARY INTAKE; DISEASE FREE SURVIVAL; HUMAN; IMMOBILIZATION; INFLAMMATION; INTERVENTION STUDY; MEDICAL LITERATURE; MEDLINE; METABOLIC DISORDER; OBESITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROGNOSIS;

EID: 74749089929     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481001700107     Document Type: Article

References (60)

1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society; 2009. http://www.cancer.org/downloads/STT/500809web. pdf. Accessed September 30, 2009.
2. Horner MJ, Ries LAG, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. http://seer.cancer. gov/csr/1975-2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009. Accessed October 1, 2009.
3. Hewitt M, Greenfield S, Stovall E, eds. From Cancer Patient to Cancer Survivor: Lost in Transition. Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council. Washington, DC: The National Academies Press; 2005.
4. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9(7):489-499.
5. Nutrition and Physical Activity Guidelines for Cancer Survivors After Treatment. AICR's Guidelines for Cancer Survivors 2009: American Institute for Cancer Research 2006. http://www.aicr.org. Accessed on October 5, 2009.
6. Hjartåker A, Langseth H, Weiderpass E. Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol. 2008;630:72-93.
7. Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98(3):484-495.
8. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134.
9. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004;22(4):648-657.
10. Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98(22):1647-1654.
11. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol. 2008;26(25):4109-4115.
12. Park SM, Lim MK, Jung KW, et al. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol. 2007;25(30): 4835-4843.
13. Park SM, Lim MK, Shin SA, et al. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol. 2006;24(31): 5017-5024.
14. Moon HG, Ju YT, Jeong CY, et al. Visceral obesity may affect oncologic outcome in patients with colorectal cancer. Ann Surg Oncol. 2008;15 (7):1918-1922.
15. Haydon AM, Macinnis RJ, English DR, et al. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut. 2006; 55(1):62-67.
16. Haydon AM, Macinnis RJ, English DR, et al. Physical activity, insulinlike growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer. Gut. 2006;55(5):689-694.
17. Hawkes AL, Pakenham KI, Courneya KS, et al. A randomised controlled trial of a tele-based lifestyle intervention for colorectal cancer survivors ('CanChange'): study protocol. BMC Cancer. 2009;9:286.
18. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007;298(7):754-764.
19. Meyerhardt JA, Sloan JA, Sargent DJ, et al. Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(6):1402-1410.
20. Lynch BM, Cerin E, Owen N, et al. Prospective relationships of physical activity with quality of life among colorectal cancer survivors. J Clin Oncol. 2008;26(27):4480-4487.
21. Gutierrez DA, Puglisi MJ, Hasty AH. Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. Curr Diab Rep. 2009;9(1):26-32.
22. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr. 2008; 32(6):638-644.
23. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4-12.
24. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772-783.
25. Ohshima H, Tatemichi M, Sawa T. Chemical basis of inflammationinduced carcinogenesis. Arch Biochem Biophys. 2003;417(1):3-11.
26. Kumor A, Daniel P, Pietruczuk M, et al. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis. 2009;24(3):275-281.
27. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90(2):215-219.
28. Miki C, Konishi N, Ojima E, et al. C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci. 2004;49(6):970-976.
29. Crozier JE, McKee RF, McArdle CS, et al. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer. 2006;94(12):1833-1836.
30. Ishizuka M, Nagata H, Takagi K, et al. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007;246(6):1047-1051.
31. Crozier JE, McKee RF, McArdle CS, et al. Preoperative but not postoperative systemic inflammatory response correlates with survival in colorectal cancer. Br J Surg. 2007;94(8):1028-1032.
32. Ishizuka M, Kita J, Shimoda M, et al. Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer. J Surg Oncol. 2009;100(1):38-42.
33. Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003; 89(6):1028-1030.
34. Glen P, Jamieson NB, McMillan DC, et al. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology. 2006;6(5):450-453.
35. Al Murri AM, Bartlett JM, Canney PA, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 2006;94(2):227-230.
36. Crumley AB, McMillan DC, McKernan M, et al. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006;94(5):637-641.
37. McMillan DC, Crozier JE, Canna K, et al. Evaluation of an inflammation based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22(8):881-886.
38. Leitch EF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97(9):1266-1270.
39. Fujita T. Influence of preoperative inflammation on outcomes of colorectal cancer surgery. Ann Surg. 2008;247(6):1084-105; author reply 1085-1086.
40. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649-658.
41. Bardia A, Ebbert JO, Vierkant RA, et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst. 2007;99(11):881-889.
42. Blair CK, Sweeney C, Anderson KE, et al. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat. 2007;101(2):191-197.
43. Kwan ML, Habel LA, Slattery ML, et al. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control. 2007;18 (6):613-620.
44. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(21):3437-3444.
45. Grau MV, Baron JA, Langholz B, et al. Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer. 2006;119(3):682-686.
46. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008;29(7):777-822.
47. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679-1687.
48. Caudle AS, Kim HJ, Tepper JE, et al. Diabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer. Ann Surg Oncol. 2008;15(7):1931-1936.
49. Jullumstrø E, Kollind M, Lydersen S, et al. Diabetes mellitus and outcomes of colorectal cancer. Acta Oncol. 2009;48(3):361-367.
50. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol. 2002; 175(1):19-31.
51. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915-928.
52. Wolpin BM, Meyerhardt JA, Chan AT, et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol. 2009;27(2):176-185.
53. Fuchs CS, Goldberg RM, Sargent DJ, et al. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res. 2008;14(24):8263-8269.
54. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, et al. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer. 2009;115(16):3609-3617.
55. Lynch BM, Cerin E, Newman B, et al. Physical activity, activity change, and their correlates in a population-based sample of colorectal cancer survivors. Ann Behav Med. 2007;34(2):135-143.
56. Hawkes AL, Gollschewski S, Lynch BM, et al. A telephone-delivered lifestyle intervention for colorectal cancer survivors 'CanChange': pilot study. Psychooncology. 2009;18(4):449-455.
57. Ballard-Barbash R, Hunsberger S, Alciati MH, et al. Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. J Natl Cancer Inst. 2009;101(9):630-643.
58. Baserga R. Customizing the targeting of IGF-1 receptor. Future Oncol. 2009;5(1):43-50.
59. Zakikhani M, Dowling RJ, Sonenberg N, et al. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila Pa). 2008;1(5): 369-375.
60. Campbell KL, Campbell PT, Ulrich CM, et al. No reduction in C-reactive protein following a 12-month randomized controlled trial of exercise in men and women. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1714-1718.